[Immunomodulatory treatment with beta-interferon in patients with cervical intraepithelial neoplasia and human papillomavirus infection: long-term follow-up].
The aim of this study was to evaluate the long-term efficacy of beta-interferon treatment in the management of cervical intraepithelial neoplasia associated with human papillomavirus (HPV) infection in a selected group of patients. Thirty-nine patients who had histologically proven cervical intraepithelial neoplasia I or II with concurrent HPV infection were administered 27,000,000 IU of intramuscular beta-interferon. Periodical controls were carried out based on Papanicolaou smears and/or colposcopic examination and DNA HPV determination was performed by hybridation test, for a maximum of 8 years' follow-up. An initial complete response rate of 75% was obtained, with a recurrence rate of 25%, cervical intraepithelial neoplasia with late manifestation was of higher grade. Treatment interruption due to side-effects was not necessary. Associated viral infections appeared to be a recurrence risk factor, but not smoking or parity. While immunomodulatory treatment with beta-interferon has good long-term results in cervical intraepithelial neoplasia I/II treatment, wider randomized studies are required to obtain conclusive results.
Cazorla
E
E
Servicio de Ginecología, Hospital Universitario La Fe, Valencia. cazorla_edu@gva.es
Urgal
A
A
Córdoba
J
J
Boldó
A
A
Marín
M
M
Sánchez Gutiérrez
M
M
Molina
J M
JM
Llixiona
J
J
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D016899:Interferon-beta / Q000627:therapeutic use*; D008875:Middle Aged; D030361:Papillomavirus Infections / Q000150:complications* / Q000188:drug therapy*; D013997:Time Factors; D002577:Uterine Cervical Diseases / Q000150:complications* / Q000188:drug therapy*; D002583:Uterine Cervical Neoplasms / Q000150:complications* / Q000188:drug therapy*; D002578:Uterine Cervical Dysplasia / Q000150:complications* / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D016899:Interferon-beta